Preferred Label : iPSC-derived Allogeneic Anti-HER2 CAR T-cells FT825;
NCIt synonyms : Allogeneic Anti-HER2 CAR T-cells FT825;
NCIt definition : An off-the-shelf (OTS) preparation of induced pluripotent stem cell (iPSC)-derived,
multiplexed-engineered alpha-beta T-lymphocytes expressing a chimeric antigen receptor
(CAR), using a specific H2CasMab-2 binder and Trac-mediated 1XX CAR, with a specific
binding domain targeting the tumor-associated antigen (TAA) human epidermal growth
factor receptor type 2 (HER2; EGFR2; ErbB2), with potential antineoplastic activity.
FT825 contains seven synthetic controls in order to manipulate cellular function,
including a CXC chemokine receptor 2 (CXCR2) to promote cell trafficking, a chimeric
tumor growth factor-beta (TGFb) signal redirection receptor (TGFb-SRR) to redirect
immunosuppressive signals, such as the immunosuppressive TGFb, in the tumor microenvironment
(TME), a CD38 knock-out (CD38 null) to improve persistence, a synthetic interleukin
(IL) 7/IL-7 receptor fusion protein (IL-7RF) to promote T-cell stemness, a T-cell
receptor (TCR) removal to reduce the risk of graft-versus-host disease (GvHD), and
a high-affinity non-cleavable CD16a receptor (hnCD16) to enable CD16-mediated antibody-dependent
cellular cytotoxicity (ADCC) upon administration of a specific therapeutic antibody.
Upon administration, allogeneic anti-HER2 CAR T-cells FT825 target, bind to and induce
selective toxicity in HER2-expressing tumors cells. This may result in the inhibition
of tumor cell proliferation. HER-2 is overexpressed in various tumor cell types.;
Molecule name : FT825/ONO-8250; FT-825; ONO 8250; ONO-8250; FT 825;
NCI Metathesaurus CUI : CL1926375;
Origin ID : C204108;
UMLS CUI : C5908026;
Semantic type(s)
- Cell [UMLS semantic type]
- concept_is_in_subset
- has_target
